SG10202101918RA - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction - Google Patents

Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Info

Publication number
SG10202101918RA
SG10202101918RA SG10202101918RA SG10202101918RA SG10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA
Authority
SG
Singapore
Prior art keywords
selenium
disease
prevention
compositions
treatment
Prior art date
Application number
SG10202101918RA
Inventor
Ronan Power
Casey Egan
Alexander Yiannikouris
Zi-Jian Lan
Rijin Xiao
Lewis Jackson
Stefan Kwiatkowski
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of SG10202101918RA publication Critical patent/SG10202101918RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
SG10202101918RA 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction SG10202101918RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10202101918RA true SG10202101918RA (en) 2021-03-30

Family

ID=51537786

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101918RA SG10202101918RA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
SG11201507061XA SG11201507061XA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507061XA SG11201507061XA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Country Status (15)

Country Link
US (1) US9833486B2 (en)
EP (1) EP2968404A4 (en)
JP (1) JP6313418B2 (en)
KR (1) KR102245702B1 (en)
CN (3) CN114533753A (en)
AU (1) AU2014228785B2 (en)
BR (1) BR112015022514A2 (en)
CA (1) CA2903845C (en)
CL (1) CL2015002677A1 (en)
HK (1) HK1216506A1 (en)
MX (1) MX359626B (en)
RU (1) RU2663127C2 (en)
SG (2) SG10202101918RA (en)
WO (1) WO2014144776A1 (en)
ZA (1) ZA201506759B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152795A2 (en) 2013-03-14 2014-09-25 Schentag Jerome J Cholestosome vesicles for incorporation of molecules into chylomicrons
KR102466389B1 (en) * 2014-03-14 2022-11-11 올텍 법인회사 Compositions of Selenoorganic Compounds and Methods of Use Thereof
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3429373A4 (en) * 2016-03-14 2019-07-17 Mitogenetics, LLC Materials and methods for treating hypoxic conditions
BR112019022918A2 (en) 2017-05-19 2020-05-26 Alltech, Inc. PHARMACEUTICAL AGENTS, COMPOSITIONS AND METHODS RELATING TO THE SAME
CN108283711A (en) * 2018-05-06 2018-07-17 冷立娟 A kind of instant particles as Chinese medicine and preparation method thereof for treating alcoholic myocardiopathy
CN109820933A (en) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 Weight-reducing tablet and preparation method thereof
CN111493325A (en) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 Application of plant selenium peptide in preparation of composition for improving obesity and metabolic syndrome
CN112129864B (en) * 2020-09-24 2022-04-01 江南大学 Method for determining selenium form in selenium-rich plant dry powder
KR102328808B1 (en) * 2020-12-02 2021-11-22 동의대학교 산학협력단 Composition for preventing and improving sarcopenia using brewer's yeast
CN114053298A (en) * 2021-11-19 2022-02-18 华中农业大学 Medicine for inhibiting myocardial hypertrophy and construction method of model
CN114235989A (en) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 High performance liquid chromatography for determining content of asomate
CN114031650B (en) * 2021-11-29 2023-05-02 上海交通大学 Chitosan oligosaccharide selenium coordination compound and preparation method and application thereof
CN114931569B (en) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 Application of methylselenocysteine in preparation of product for improving male reproductive capacity
CN116333302A (en) * 2023-03-31 2023-06-27 中南大学 Stable and durable antioxidant nano-dot and application thereof in type II diabetes
CN116421618B (en) * 2023-06-15 2023-09-29 暨南大学 Preparation method of Se@NADH and application of Se@NADH in spinal cord injury treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (en) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル Platinum toxicity detoxicant
WO2004107881A1 (en) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
PL214402B1 (en) * 2003-08-11 2013-07-31 Tomasz Byrski Pharmaceutical compound, application of selenium or its compounds as well as the method for reducing breast or ovary cancer hazard
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN102764279B (en) * 2005-10-14 2015-04-01 全面技术公司 Method and composition for modifying cyte functions
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008144543A2 (en) * 2007-05-18 2008-11-27 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
NZ583025A (en) * 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin Method for the selective therapy of disease
ES2378595T3 (en) * 2007-10-16 2012-04-16 Actigenomics S.A. Composition for the regulation of lipid metabolism
CN101579355B (en) * 2009-05-27 2010-12-08 徐建兴 Nutrition composition used for maintaining functions of mitochondria and application thereof
WO2011047434A1 (en) * 2009-10-22 2011-04-28 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
US8883498B2 (en) * 2010-04-22 2014-11-11 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (en) * 2010-11-05 2012-05-15 한국식품연구원 Composition for prevention and treatment of obesity and metabolic diseases comprising methylselenocysteine
KR102100091B1 (en) 2011-04-13 2020-04-14 아지노모토 가부시키가이샤 Nutritional composition

Also Published As

Publication number Publication date
US9833486B2 (en) 2017-12-05
ZA201506759B (en) 2017-03-29
NZ711842A (en) 2021-04-30
CA2903845A1 (en) 2014-09-18
CN105377271A (en) 2016-03-02
CA2903845C (en) 2022-08-23
CN114984038A (en) 2022-09-02
HK1216506A1 (en) 2016-11-18
EP2968404A1 (en) 2016-01-20
RU2663127C2 (en) 2018-08-01
EP2968404A4 (en) 2017-01-04
MX2015013275A (en) 2015-12-11
JP2016516058A (en) 2016-06-02
KR20150132374A (en) 2015-11-25
CL2015002677A1 (en) 2016-12-09
KR102245702B1 (en) 2021-04-28
BR112015022514A2 (en) 2017-07-18
RU2015139742A (en) 2017-04-21
SG11201507061XA (en) 2015-10-29
CN114533753A (en) 2022-05-27
MX359626B (en) 2018-10-01
US20160113977A1 (en) 2016-04-28
JP6313418B2 (en) 2018-04-18
WO2014144776A1 (en) 2014-09-18
AU2014228785A1 (en) 2015-09-24
AU2014228785B2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
HK1216506A1 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
HK1250910A1 (en) Combination of vaccination and inhibition of the pd-1 pathway
IL256624B (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL242483B (en) Omomyc compositions and the use thereof for the treatment of cancer
HK1221874A1 (en) Use of a composition comprising fish oil and juice for the treatment and or post treatment of cancer
EP2961420A4 (en) Methods and compositions for the prevention or treatment of barth syndrome
IL244622A0 (en) Compositions for the treatment of hypertension and/or fibrosis
IL244621A (en) Compositions for the treatment of hypertension and/or fibrosis
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
HK1225994A1 (en) Compositions for use in the treatment of allergic conditions
EP2948219A4 (en) Targeting the steroidogenic pathway for treating and/or preventing allergic diseases
EP2964750A4 (en) Methods and compositions for the treatment and/or prevention of type 1 diabetes
PT2862576T (en) Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis
IL259383A (en) Compound for use in the prevention and treatment of neurodegenerative diseases
IL245998A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
PL3041459T3 (en) Compositions useful in the prevention or treatment of skin cancer
GB201316698D0 (en) Use of tri-substituted glycerol compounds for prevention and treatment of allo-immune disorders